Table 3.

Select clinical trials of tyrosine kinase inhibitors and other anti-angiogenic compounds in prostate cancer.

Phase	Regimen	Goal N	Clinical Trials ID
AZD-2171 (Cediranib)
II	AZD-2171 and prednisone in metastatic CRPC	37	NCT00436956
II	Docetaxel and prednisone with or without cediranib	104	NCT00527124
Sorafenib
I/II	Concurrent sorafenib, ADT and radiation therapy for initial treatment of intermediate and high risk localized prostate cancer	50	NCT00924807
II	Sorafenib and docetaxel for mCRPC	69	NCT00589420
Sunitinib
II	Sunitinib with docetaxel and prednisone in chemotherapy naïve metastatic CRPC	30	NCT00879619
II	Docetaxel, sunitinib and prednisone followed by EBRT for men with biochemical recurrence following radical prostatectomy	38	NCT00734851
II	Neoadjuvant sunitinib and hormonal ablation for patients who will have prostatectomy	42	NCT00329043
III	Prednisone with or without sunitinib in CRPC patients who have failed docetaxel	819	NCT00676650
Pazopanib
II	Pazopanib after failure of total androgen blockade	34	NCT00945477
II	Pazopanib with or without bicalutamide in mCRPC	74	NCT00486642
Vandetanib
II	ZD 6474 (Vandetanib) with Bicalutamide versus Bicalutamide alone in chemotherapy naïve CRPC	74	NCT00757692
II	Randomized placebo controlled trial of vandetanib and bicalutamide versus bicalutamide alone in metastatic CRPC	90	NCT00659438
Other anti-angiogenic agents
I	Docetaxel/Prednisone and 177 Lu-J591 antibody for mCRPC	30	NCT00916123
II	177Lu-J591 and ketoconazole/hydrocortisone in high risk nonmetastatic CRPC	140	NCT00859781